Anyone here think resveratrol is too much of a risk at this time?
Why? Doses?
Posted 01 February 2008 - 04:11 PM
Posted 01 February 2008 - 06:27 PM
Anyone here think resveratrol is too much of a risk at this time?
Why? Doses?
Posted 01 February 2008 - 06:56 PM
Anyone here think resveratrol is too much of a risk at this time?
Why? Doses?
Too risky for who? At my age, 70+, it seems like a reasonable bet for better health. Has lots of subjective benefits too.
Posted 02 February 2008 - 04:07 PM
Some of the early papers on resveratrol suggested it might have an estrogenic effect, and contribute to breast cancer, but the opposite was found to be the case. Apparently resveratrol may prevent prostate cancer as well.Anyone here think resveratrol is too much of a risk at this time?
Why? Doses?
Too risky for who? At my age, 70+, it seems like a reasonable bet for better health. Has lots of subjective benefits too.
Well, that's my question. Is it in fact too risky?
Age 70. Okay. Is there any evidence that resveratrol could promote growth in prostate cancer cells? Most elderly men do in fact have some malignant cells in the prostate.
Edited by maxwatt, 02 February 2008 - 04:40 PM.
Posted 02 February 2008 - 04:58 PM
Some of the early papers on resveratrol suggested it might have an estrogenic effect, and contribute to breast cancer, but the opposite was found to be the case. Apparently resveratrol may prevent prostate cancer as well.
Possible role of resveratrol in prevention of prostate carcinogenesis
The only possible negative effect of resveratrol of which I am currently aware, is that it may aggravate certain autoimmune diseases, such as lupus and rheumatoid arthritis. This is not definite, though.
Edited for speling and gramer
Edited by caston, 02 February 2008 - 05:01 PM.
Posted 02 February 2008 - 05:46 PM
Some of the early papers on resveratrol suggested it might have an estrogenic effect, and contribute to breast cancer, but the opposite was found to be the case. Apparently resveratrol may prevent prostate cancer as well.
Possible role of resveratrol in prevention of prostate carcinogenesis
The only possible negative effect of resveratrol of which I am currently aware, is that it may aggravate certain autoimmune diseases, such as lupus and rheumatoid arthritis. This is not definite, though.
Edited for speling and gramer
My understanding was the res is not as accurate as we would like it to be in terms of it hits a few longevity genes and a few others to boot. I think something has or will come out that is better than res but rest is still quite a good choice but definately take it with other flavinoids and phytochemicals as part of a diverse stack.
Andy Dillan has been targeting PHA-4.
""We know three distinct pathways that affect longevity: insulin/IGF signaling, calorie restriction, and the mitochondrial electron transport chain pathway, yet it is still not clear where sir-2 fits in. It seems to meddle with more than one pathway," says Dillin and adds that "PHA-4 is specific for calorie restriction as it does not affect the other pathways.""
http://www.pha4.com/
Posted 02 February 2008 - 07:12 PM
'Red wine' based drug may fight cancer
By Roger Highfield, Science Editor
Last Updated: 10:01am GMT 31/01/2008
Evidence that an antiageing drug based on a key ingredient of red wine could have anticancer effects too has been found, paving the way for human trials this year.
Tests are under way on diabetics of SRT501, an improved formulation of resveratrol, a wine chemical, that could lead to a family of new drugs with powerful effects against the diseases of ageing as well as adult diabetes, the developed world's fastest-growing degenerative disease.
The drug targets SIRT1, the founding member of the human sirtuin family of enzymes which control the ageing process. Now two teams report in the journal Nature how SIRT1 plays a role in tumour growth.
The American groups, respectively led by Drs Junjie Chen of Yale University and Wei Gu of Columbia University and their colleagues, have discovered that another protein, named DBC1, acts as a regulator of SIRT: lower levels help damaged cells to self destruct and higher ones make cells susceptible to damage to a process called oxidative stress.
Although this suggests that drugs such as SRT501 could promote tumour growth in some circumstances, Dr Chen said that more research needs to be done to confirm this. "This assmption really needs to be studied."
And tests by the developers of SIRT1, the American company Sirtris suggest the drug does have anticancer effects. Prof David Sinclair, who pioneered the SRT501 work at Harvard Medical School, comments: "Genetic upregulation of SIRT1 suppresses cancer in the gold standard mouse. There are over 50 published in vitro and in vivo papers showing that SIRT1 activation improves cancer.
"Based on the data, Sirtris is planning to initiate a trial in cancer with SIRT1 activators in patients in either the US or Europe or both in the first half of 2008.," he adds.
The SIRT1 drugs emerged from research to understand why all species live longer on a calorie-restricted diet. So long as there is adequate nutrition, cutting calories by 40 per cent prolongs lifespan by 50 per cent or more in yeast, mice, rats and every other species so far tested.
http://www.telegraph.../sciwine130.xml
The NAD-dependent protein deacetylase Sir2 (silent information regulator 2) regulates lifespan in several organisms1, 2, 3. SIRT1, the mammalian orthologue of yeast Sir2, participates in various cellular functions4, 5, 6, 7 and possibly tumorigenesis8. Whereas the cellular functions of SIRT1 have been extensively investigated, less is known about the regulation of SIRT1 activity. Here we show that Deleted in Breast Cancer-1 (DBC1), initially cloned from a region (8p21) homozygously deleted in breast cancers9, forms a stable complex with SIRT1. DBC1 directly interacts with SIRT1 and inhibits SIRT1 activity in vitro and in vivo. Downregulation of DBC1 expression potentiates SIRT1-dependent inhibition of apoptosis induced by genotoxic stress. Our results shed new light on the regulation of SIRT1 and have important implications in understanding the molecular mechanism of ageing and cancer.
Posted 03 February 2008 - 03:42 AM
Posted 03 February 2008 - 08:00 AM
Posted 20 May 2008 - 05:13 AM
....
May 16, 2008 (Orlando, Florida) — New research suggests that resveratrol, a chemical commonly found in red wine, has the ability to lower blood-sugar levels, but it might also produce certain unpleasant adverse effects.
The research was presented here at the American Association of Clinical Endocrinologists 17th Annual Meeting and Clinical Congress by Kimberly Martin, MD, a pediatric endocrinology fellow at Case Western Reserve University in Cleveland, Ohio.
....
The research, however, shows that in cells expressing the GLUT1 isoform, resveratrol blocks glucose transport by binding and inhibiting the GLUT1 transporter. This could be key because certain cells and tissues, including brain, retina, placenta, and red blood cells, express large amounts of this transporter. The presumed inhibition of the GLUT1 transporter in these tissues in vivo might therefore have undesired and negative effects on their normal function.
"This is a potential medication that could be used in multiple areas," Dr. Martin said. "The concern is that you could lower glucose in diabetics but at the same time. . . [lower] glucose levels in the brain or in other important tissues."
Posted 20 May 2008 - 06:21 AM
http://www.medscape....sdmh=dm1.352815
....
May 16, 2008 (Orlando, Florida) — New research suggests that resveratrol, a chemical commonly found in red wine, has the ability to lower blood-sugar levels, but it might also produce certain unpleasant adverse effects.
The research was presented here at the American Association of Clinical Endocrinologists 17th Annual Meeting and Clinical Congress by Kimberly Martin, MD, a pediatric endocrinology fellow at Case Western Reserve University in Cleveland, Ohio.
....
The research, however, shows that in cells expressing the GLUT1 isoform, resveratrol blocks glucose transport by binding and inhibiting the GLUT1 transporter. This could be key because certain cells and tissues, including brain, retina, placenta, and red blood cells, express large amounts of this transporter. The presumed inhibition of the GLUT1 transporter in these tissues in vivo might therefore have undesired and negative effects on their normal function.
"This is a potential medication that could be used in multiple areas," Dr. Martin said. "The concern is that you could lower glucose in diabetics but at the same time. . . [lower] glucose levels in the brain or in other important tissues."
Posted 20 May 2008 - 07:42 AM
[url="http://www.medscape....mh=dm1.352815"]
The research, however, shows that in cells expressing the GLUT1 isoform, resveratrol blocks glucose transport by binding and inhibiting the GLUT1 transporter. This could be key because certain cells and tissues, including brain, retina, placenta, and red blood cells, express large amounts of this transporter. The presumed inhibition of the GLUT1 transporter in these tissues in vivo might therefore have undesired and negative effects on their normal function.
"This is a potential medication that could be used in multiple areas," Dr. Martin said. "The concern is that you could lower glucose in diabetics but at the same time. . . [lower] glucose levels in the brain or in other important tissues."
Why would lower sugar in the brain be bad, but a good effect in other tissues? Won't brain cells be adversely affected by high/higher glucose levels? I guess it depends on how low the glucose goes.
Posted 20 May 2008 - 11:48 AM
http://www.medscape....sdmh=dm1.352815
....
May 16, 2008 (Orlando, Florida) — New research suggests that resveratrol, a chemical commonly found in red wine, has the ability to lower blood-sugar levels, but it might also produce certain unpleasant adverse effects.
The research was presented here at the American Association of Clinical Endocrinologists 17th Annual Meeting and Clinical Congress by Kimberly Martin, MD, a pediatric endocrinology fellow at Case Western Reserve University in Cleveland, Ohio.
....
The research, however, shows that in cells expressing the GLUT1 isoform, resveratrol blocks glucose transport by binding and inhibiting the GLUT1 transporter. This could be key because certain cells and tissues, including brain, retina, placenta, and red blood cells, express large amounts of this transporter. The presumed inhibition of the GLUT1 transporter in these tissues in vivo might therefore have undesired and negative effects on their normal function.
"This is a potential medication that could be used in multiple areas," Dr. Martin said. "The concern is that you could lower glucose in diabetics but at the same time. . . [lower] glucose levels in the brain or in other important tissues."
Why would lower sugar in the brain be bad, but a good effect in other tissues? Won't brain cells be adversely affected by high/higher glucose levels? I guess it depends on how low the glucose goes.
Posted 20 May 2008 - 12:08 PM
Posted 20 May 2008 - 12:08 PM
http://www.medscape....sdmh=dm1.352815
....
May 16, 2008 (Orlando, Florida) — New research suggests that resveratrol, a chemical commonly found in red wine, has the ability to lower blood-sugar levels, but it might also produce certain unpleasant adverse effects.
The research was presented here at the American Association of Clinical Endocrinologists 17th Annual Meeting and Clinical Congress by Kimberly Martin, MD, a pediatric endocrinology fellow at Case Western Reserve University in Cleveland, Ohio.
....
The research, however, shows that in cells expressing the GLUT1 isoform, resveratrol blocks glucose transport by binding and inhibiting the GLUT1 transporter. This could be key because certain cells and tissues, including brain, retina, placenta, and red blood cells, express large amounts of this transporter. The presumed inhibition of the GLUT1 transporter in these tissues in vivo might therefore have undesired and negative effects on their normal function.
"This is a potential medication that could be used in multiple areas," Dr. Martin said. "The concern is that you could lower glucose in diabetics but at the same time. . . [lower] glucose levels in the brain or in other important tissues."
Why would lower sugar in the brain be bad, but a good effect in other tissues? Won't brain cells be adversely affected by high/higher glucose levels? I guess it depends on how low the glucose goes.
Other studies demonstrate a neuro-protective effect of resveratrol against glucose deprivation in brain cells:
Protective effect of resveratrol against oxygen-glucose deprivation in organotypic hippocampal slice cultures: Involvement of PI3-K pathway.
Resveratrol inhibits interleukin-6 production in cortical mixed glial cells under hypoxia/hypoglycemia followed by reoxygenation.
Posted 21 May 2008 - 06:12 AM
The research, however, shows that in cells expressing the GLUT1 isoform, resveratrol blocks glucose transport by binding and inhibiting the GLUT1 transporter. This could be key because certain cells and tissues, including brain, retina, placenta, and red blood cells, express large amounts of this transporter. The presumed inhibition of the GLUT1 transporter in these tissues in vivo might therefore have undesired and negative effects on their normal function.
Of all cells, human erythrocytes express the highest level of the Glut1 glucose transporter. However, the regulation and function of Glut1 during erythropoiesis are not known. Here, we report that glucose transport actually decreases during human erythropoiesis despite a >3-log increase in Glut1 transcripts. In contrast, Glut1-mediated transport of L-dehydroascorbic acid (DHA), an oxidized form of ascorbic acid (AA), is dramatically enhanced. We identified stomatin, an integral erythrocyte membrane protein, as regulating the switch from glucose to DHA transport. Notably though, we found that erythrocyte Glut1 and associated DHA uptake are unique traits of humans and the few other mammals that have lost the ability to synthesize AA from glucose. Accordingly, we show that mice, a species capable of synthesizing AA, express Glut4 but not Glut1 in mature erythrocytes. Thus, erythrocyte-specific coexpression of Glut1 with stomatin constitutes a compensatory mechanism in mammals that are unable to synthesize vitamin C.
Posted 21 May 2008 - 09:15 PM
However, the addition of resveratrol to the same cells markedly inhibited glucose transport (half maximal effective concentration [EC50] of ~25 mmol/L) — whether or not AMPK phosphorylation was augmented or suppressed.
0 members, 1 guests, 0 anonymous users